Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The lysosome is a membrane-bound organelle in eukaryotic cells responsible for degrading and recycling macromolecules. In cancer, lysosomes support increased metabolic demands, cell survival under stress, tumor progression, and therapy resistance. It is the target for cancer therapeutics such as antibody-drug conjugates (ADCs), that release their cytotoxic payload within the lysosome. Targeting the lysosome enables selective intracellular drug release using acid-sensitive or enzyme-cleavable linkers. However, lysosomes have a dual role in tumor biology; they promote autophagic clearance but also support metabolic adaptation and enable invasion/metastasis.
Site for selective payload release from ADCs/small molecules using acid-sensitive/enzyme-cleavable linkers
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cancer Cell Lysosome (None).